Silexion announces 1-for-15 reverse share split effective July 29

GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ:SLXN), a clinical-stage biotechnology company focused on RNA interference therapies for KRAS-driven cancers, announced Wednesday a 1-for-15 reverse share split of its ordinary shares. The company, currently valued at $6.4 million, has seen its stock decline 99% over the past year according to InvestingPro data.

The reverse split will take effect after market close on July 28, 2025, with trading on a split-adjusted basis beginning at market open on July 29, 2025, under the existing SLXN ticker symbol.

As part of the adjustment, every fifteen ordinary shares will be automatically combined into one share, with the par value increasing proportionately from $0.0009 to $0.0135 per share. Shareholders entitled to fractional shares through the DTC system will receive a rounded-up whole share.

Shareholders holding shares in book-entry form or through brokers will not need to take any action, as their shares will be adjusted automatically.

The company stated the reverse split is primarily intended to help Silexion regain and maintain compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2).

"Our decision to implement this reverse share split reflects Silexion’s unwavering commitment to maintaining our Nasdaq listing and strengthening our foundation for future growth," said Ilan Hadar, Chairman and CEO of Silexion, according to the company’s press release. The company faces significant financial challenges, with InvestingPro data showing negative EBITDA of $12.55 million and a concerning current ratio of 0.64, indicating potential liquidity issues.

Silexion’s first-generation product, LODER, has completed a Phase 2 trial for non-resectable pancreatic cancer, while the company is also advancing SIL204, a next-generation siRNA candidate targeting KRAS mutations.

The information in this article is based on a company press release statement.

In other recent news, Silexion Therapeutics Corp announced that shareholders approved key measures during its annual meeting, including board elections and a reverse share split at a 1-for-15 ratio. The company also ratified the appointment of Kesselman & Kesselman as independent public accountants. Additionally, Silexion received approval from a Nasdaq hearings panel to continue its listing on the exchange, contingent on meeting specific compliance conditions. The company’s shares will be transferred to the Nasdaq Capital Market. In a significant research development, Silexion reported promising preclinical data for its candidate SIL204, showing substantial inhibition of tumor cell proliferation in KRAS-driven cancers. The company plans further studies on lung cancer cell lines. Silexion also announced a strategic collaboration with Catalent to enhance the development of SIL204, focusing on optimizing formulations for cancer treatment. This partnership aims to advance SIL204 toward human clinical trials by 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.